Skip to main content
Midterm outcomes of transmyocardial laser revascularization with intramyocardial injection of adipose derived stromal cells for severe refractory angina.
- Author(s): Konstanty-Kalandyk, Janusz;
- Bartuś, Krzysztof;
- Piątek, Jacek;
- Vuddanda, Venkat;
- Lee, Randall;
- Kędziora, Anna;
- Sadowski, Jerzy;
- Lakkireddy, Dhanunjaya;
- Kapelak, Bogusław
- et al.
Published Web Locationhttps://doi.org/10.5114/aic.2018.76409
IntroductionRefractory angina has limited effective therapeutic options and often contributes to frequent hospitalizations, morbidity and impaired quality of life.
AimWe sought to examine midterm results of a bio-interventional therapy combining transmyocardial laser revascularization (TMLR) and intramyocardial injection of adipose derived stem cells (ADSC) in patients with refractory angina not amenable to percutaneous or surgical revascularization.
Material and methodsWe included 15 patients with severe refractory angina and anterior wall ischemia who were ineligible for revascularization strategies. Adipose tissue was harvested and purified, giving the stem cell concentrate. All patients underwent left anterior thoracotomy and TMLR using a low-powered holmium : yttrium-aluminum-garnet laser and intramyocardial injection of ADSC using a combined delivery system.
ResultsNo deaths or major adverse cardiovascular or cerebrovascular events were observed in the 6-month follow-up. Mean ejection fraction increased from 35% to 38%, and mean Canadian Cardiovascular Society Angina Score decreased from 3.2 to 1.4, with decreased necessity of nitrate usage. Seventy-three percent of patients reported health improvement particularly regarding general health and bodily pain. Improvement in endocardial movement, myocardial thickening and stroke volume index (35.26 to 46.23 ml/m2) on cardiac magnetic resonance imaging (MRI) was observed in 3 patients who had repeat CMR imaging after 6 months.
ConclusionsOur study suggested that interventional therapy combining TMLR with intramyocardial implantation of ADSC may reduce symptoms and improve quality of life in patients with refractory angina. These early findings need further validation in large scale randomized controlled trials.
For improved accessibility of PDF content, download the file to your device.